Immortal Time and Selection Biases in Study of Direct-Acting Antiviral Treatment and Hepatitis C Outcomes-Reply

被引：0
|
作者：
Ogawa, Eiichi [1 ]
Yeo, Yee Hui [2 ]
Nguyen, Mindie H. [3 ,4 ]
机构：
[1] Kyushu Univ Hosp, Dept Gen Internal Med, Fukuoka, Japan
[2] Cedars Sinai Med Ctr, Div Gastroenterol & Hepatol, Los Angeles, CA USA
[3] Stanford Univ, Div Gastroenterol & Hepatol, Med Ctr, 750 Welch Rd,Ste 210, Palo Alto, CA 94304 USA
[4] Stanford Univ, Med Ctr, Dept Epidemiol & Populat Hlth, Palo Alto, CA 94304 USA
来源：
JAMA INTERNAL MEDICINE | 2023年 / 183卷 / 06期
关键词：
D O I：
10.1001/jamainternmed.2023.0557
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：626 / 626
页数：1
相关论文
共 50 条
  • [21] Direct-acting antiviral retreatment patterns for hepatitis C
    Al Hasan, Shaquib
    Dauner, Daniel G.
    Rajpurohit, Abhijeet
    Farley, Joel F.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (10): : 1100 - 1110
  • [22] Outcomes using direct-acting antiviral hepatitis-C treatment in older versus younger Veterans
    Blanquicett, Carmelo J.
    Raavi, Tapasya
    Mirk, Anna
    Johnson, Theodore M., II
    Jaglal, Michael
    Cartwright, Emily J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 (12) : 3602 - 3607
  • [23] Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia
    de Graaff, Barbara
    Yee, Kwang Chien
    Clarke, Philip
    Palmer, Andrew
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (04) : 495 - 502
  • [24] Liver Transplantation for Hepatitis C Patients in the Era of Direct-Acting Antiviral Treatment
    Khan, Adeel
    Adams, Nathaniel
    Vachharajani, Neeta
    Dageforde, Leigh Anne
    Wellen, Jason
    Shenoy, Surendra
    Doyle, Majella
    Chapman, William
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 64 - 64
  • [25] Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
    Mathur, Poonam
    Kottilil, Shyamasundaran
    Wilson, Eleanor
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2018, 6 (04) : 431 - 437
  • [26] Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia
    Barbara de Graaff
    Kwang Chien Yee
    Philip Clarke
    Andrew Palmer
    Applied Health Economics and Health Policy, 2018, 16 : 495 - 502
  • [27] Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu
    Driedger, Matt
    Galanakis, Chrissi
    Doyle, Mary-Anne
    Cooper, Curtis L.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (02) : 260 - 266
  • [28] Impact of direct-acting antiviral (DAA) treatment for hepatitis C on pulmonary hemodynamics
    Orizaga Franco, Tanya Elisa
    Blanco Vich, Isabel
    Slens, Sabela
    Alvarado, Edilmar
    Marino, Zoe
    Torras, Xavier
    Baiges, Anna
    Turon, Fanny
    Hernandez-Gea, Virginia
    Villanueva, Candid
    Moises, Jorge
    Forns, Xavier
    Carles Garcia-Pagan, Joan
    Barbera Mir, Joan Albert
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [29] Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
    Akamatsu, Nobuhisa
    Togashi, Junichi
    Hasegawa, Kiyoshi
    Kokudo, Norihiro
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S598 - S602
  • [30] New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014
    Cornberg, M.
    Siederdissen, C. Hoener Zu
    Maasoumy, B.
    Manns, M. P.
    INTERNIST, 2014, 55 (04): : 390 - +
12345